On q12 h glargine (4.5–6.5 units per day; 2–3.5 units per injection; Lantus, Sanofi-Aventis) there appeared to be no difference in the pattern of glucose responses (Fig. 2b), again limiting the total daily dose of insulin that could be delivered without an unacceptable risk of hypoglycemia. Here, INS is linked to Hypoglycemia.